Literature DB >> 11553815

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

T Sørlie1, C M Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, M B Eisen, M van de Rijn, S S Jeffrey, T Thorsen, H Quist, J C Matese, P O Brown, D Botstein, P E Lønning, A L Børresen-Dale.   

Abstract

The purpose of this study was to classify breast carcinomas based on variations in gene expression patterns derived from cDNA microarrays and to correlate tumor characteristics to clinical outcome. A total of 85 cDNA microarray experiments representing 78 cancers, three fibroadenomas, and four normal breast tissues were analyzed by hierarchical clustering. As reported previously, the cancers could be classified into a basal epithelial-like group, an ERBB2-overexpressing group and a normal breast-like group based on variations in gene expression. A novel finding was that the previously characterized luminal epithelial/estrogen receptor-positive group could be divided into at least two subgroups, each with a distinctive expression profile. These subtypes proved to be reasonably robust by clustering using two different gene sets: first, a set of 456 cDNA clones previously selected to reflect intrinsic properties of the tumors and, second, a gene set that highly correlated with patient outcome. Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553815      PMCID: PMC58566          DOI: 10.1073/pnas.191367098

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Significance analysis of microarrays applied to the ionizing radiation response.

Authors:  V G Tusher; R Tibshirani; G Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

2.  Gene-expression profiles in hereditary breast cancer.

Authors:  I Hedenfalk; D Duggan; Y Chen; M Radmacher; M Bittner; R Simon; P Meltzer; B Gusterson; M Esteller; O P Kallioniemi; B Wilfond; A Borg; J Trent; M Raffeld; Z Yakhini; A Ben-Dor; E Dougherty; J Kononen; L Bubendorf; W Fehrle; S Pittaluga; S Gruvberger; N Loman; O Johannsson; H Olsson; G Sauter
Journal:  N Engl J Med       Date:  2001-02-22       Impact factor: 91.245

3.  Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement.

Authors:  F Battaglia; G Scambia; S Rossi; P B Panici; R Bellantone; G Polizzi; P Querzoli; R Negrini; S Iacobelli; F Crucitti
Journal:  Eur J Cancer Clin Oncol       Date:  1988-11

4.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

5.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

6.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

7.  The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients.

Authors:  L Vollenweider-Zerargui; L Barrelet; Y Wong; T Lemarchand-Béraud; F Gómez
Journal:  Cancer       Date:  1986-03-15       Impact factor: 6.860

8.  Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators.

Authors:  E R Fisher; J Costantino; B Fisher; C Redmond
Journal:  Cancer       Date:  1993-03-15       Impact factor: 6.860

9.  Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy.

Authors:  J Bergh; T Norberg; S Sjögren; A Lindgren; L Holmberg
Journal:  Nat Med       Date:  1995-10       Impact factor: 53.440

10.  The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease.

Authors:  J M Howat; D M Barnes; M Harris; R Swindell
Journal:  Br J Cancer       Date:  1983-05       Impact factor: 7.640

View more
  2000 in total

1.  Three color cDNA microarrays: quantitative assessment through the use of fluorescein-labeled probes.

Authors:  Martin J Hessner; Xujing Wang; Katie Hulse; Lisa Meyer; Yan Wu; Steven Nye; Sun-Wei Guo; Soumitra Ghosh
Journal:  Nucleic Acids Res       Date:  2003-02-15       Impact factor: 16.971

2.  Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays.

Authors:  Chih Long Liu; Wijan Prapong; Yasodha Natkunam; Ash Alizadeh; Kelli Montgomery; C Blake Gilks; Matt van de Rijn
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

3.  TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Authors:  Lisa A Carey; Hope S Rugo; P Kelly Marcom; Erica L Mayer; Francisco J Esteva; Cynthia X Ma; Minetta C Liu; Anna Maria Storniolo; Mothaffar F Rimawi; Andres Forero-Torres; Antonio C Wolff; Timothy J Hobday; Anastasia Ivanova; Wing-Keung Chiu; Madlyn Ferraro; Emily Burrows; Philip S Bernard; Katherine A Hoadley; Charles M Perou; Eric P Winer
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

Review 4.  Stem cells in the human breast.

Authors:  Ole William Petersen; Kornelia Polyak
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05       Impact factor: 10.005

Review 5.  Histological types of breast cancer: how special are they?

Authors:  Britta Weigelt; Felipe C Geyer; Jorge S Reis-Filho
Journal:  Mol Oncol       Date:  2010-04-18       Impact factor: 6.603

6.  Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

Authors:  Marco Colleoni; Bernard F Cole; Giuseppe Viale; Meredith M Regan; Karen N Price; Eugenio Maiorano; Mauro G Mastropasqua; Diana Crivellari; Richard D Gelber; Aron Goldhirsch; Alan S Coates; Barry A Gusterson
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

7.  Role of hypoxia and EGF on expression, activity, localization and phosphorylation of carbonic anhydrase IX in MDA-MB-231 breast cancer cells.

Authors:  Ying Li; Hai Wang; Chingkuang Tu; Kathleen T Shiverick; David N Silverman; Susan C Frost
Journal:  Biochim Biophys Acta       Date:  2010-10-12

8.  Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models.

Authors:  Huiping Liu; Manishkumar R Patel; Jennifer A Prescher; Antonia Patsialou; Dalong Qian; Jiahui Lin; Susanna Wen; Ya-Fang Chang; Michael H Bachmann; Yohei Shimono; Piero Dalerba; Maddalena Adorno; Neethan Lobo; Janet Bueno; Frederick M Dirbas; Sumanta Goswami; George Somlo; John Condeelis; Christopher H Contag; Sanjiv Sam Gambhir; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

9.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors:  Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

10.  Igf1r as a therapeutic target in a mouse model of basal-like breast cancer.

Authors:  Apostolos Klinakis; Matthias Szabolcs; Guoying Chen; Shouhong Xuan; Hanina Hibshoosh; Argiris Efstratiadis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.